Anaxomics, a CataloniaBio & HealthTech member, has moved to new offices on Carrer de la Diputació in Barcelona ahead of expected growth over the coming three years. The bioinformatics company also has offices in Lausanne (Switzerland) and London (United Kingdom).

In 2019, Anaxomics sales were up 60% (from revenue of €465,000 in 2018) and it now has a portfolio of over 70 clients, including large pharmaceutical companies (Pfizer, Novartis, Roche, Sobi, UCB, etc.) and hospitals (Clinic, Dotze d’Octubre, Germans Trias i Pujol, Vall d’Hebron, etc.). The bioinformatics company has a staff of 25 professionals and expects to hire new PhDs next year.

As the company's Business Development Director Dr Mireia Coma told CataloniaBioHT, Anaxomics has two lines of business focusing on personalised medicine: “The services we offer with Therapeutic Performance Mapping System (TPMS) technology that simulates the human body and how it interacts with drugs, using artificial intelligence; and collaborative research.”

TPMS is used for projects in preclinical phases to find new indications, those in the clinical phases to understand side effects, and when the drugs are already on the market, for repositioning. In a recent success story, Dr Caty Casas at the Autonomous University of Barcelona Institute of Neuroscience used TPMS to identify a combination of drugs for repositioning. Then the repositioned drug was validated in an animal model with peripheral nerve damage and the spin-off NeuroHeal Biomedicals was created to take it to market.

The Anaxomics R&D unit is currently working on ten projects and five European consortia funded by the Horizon 2020 programme to advance research on cancer, irritable bowel, type-2 diabetes and tuberculosis.

Photo: from left to right, Dr José Manuel Mas, founder and CEO; Dr Mireia Coma, Business Development Director; and Dr Judith Farrés, head of Collaborative Research.